| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3584903efe1babebbd056e855a2cc2b3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2014-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc8069d0bf86a96b05318cfc670a940f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab9bf92e6fa2bf87c4de4775e06c1e97 |
| publicationDate |
2016-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160069667-A |
| titleOfInvention |
A novel anticancer agent targeting epidermal growth factor receptor |
| abstract |
The present invention provides a pharmaceutical composition for the treatment of cancer characterized by overexpression or abnormal activation of EGFR containing anti-EGFR lipid body as an active ingredient for a more economical and effective treatment of cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101875809-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018212540-A3 |
| priorityDate |
2014-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |